Elemer Piros

PharmAthene Inc. (NASDAQ: PIP)(FREE stock trend analysis) has recently announced that an rPA proposal has been canceled due to BARDA’s concern about SparVax licensure within 8 years. However, the firm has noted that it plans to continue developing SparVax as planned earlier. PharmAthene Inc also...

According to a report released by Rodman & Renshaw, Repligen Corp.(NASDAQ: RGEN)(FREE stock trend analysis) failed to meet the specified primary end-points for the phase 3 study of RG1068. Since, RG1068 is expected to have only marginal commercial potential, Rodman & Renshaw analyst Elemer...